MADRID, Spain — September 30, 2026 — Kenneth Scott and Helga Sands have a problem that much of the longevity industry hopes one day to create for millions of people: they have already achieved longevity.
Scott was born in 1942. Sands was born in 1938. Both have reached their ninth decade. Neither is particularly interested in simply adding more years accompanied by declining physical or cognitive function.
“Longevity is for youngsters,” Scott says. “Helga and I have already achieved longevity. We don’t want simply to live older. We want to become younger—to restore function that has been lost.”
That conviction led Scott and Sands to create the KHL Foundation, focused on bringing rejuvenative therapies to older people who are already experiencing age-related decline and do not have decades to wait for conventional development pathways.
KHL works with scientists, physicians and biotechnology developers to help develop and adapt promising rejuvenation technologies for practical human application, beginning with the generation that needs them now.
Its operating process is DAMA: Develop → Apply → Monitor → Adapt.
At the International Longevity Summit in Madrid on September 30, Scott will publicly present two applications of that approach: early human experience with KHL’s three-gene Rejuvenation Cocktail, and previously unreported human treatments involving an experimental 11-gene therapy containing the partial cellular reprogramming factors OCT4, SOX2 and KLF4—collectively known as OSK.
Human OSK Treatments — 2026
A small number of people have received an experimental 11-gene therapy containing OSK developed through a Triple Helix Science initiative.
One of those recipients, Christine Scott, received the treatment on March 11, 2026. The therapy was administered submucosally with cognitive function as its principal target. Expression of the OSK components is controlled through a doxycycline activation regimen.
The underlying gene-therapy initiative is led by Patrick Sewell, MD, and Triple Helix Science. KHL is supporting the initiative, including through the participation and monitoring of Christine Scott, who experienced substantial cognitive and neurological decline following a severe adverse reaction attributed to ciprofloxacin.
To the best knowledge of Sewell, Scott and Sands, these treatments represent the first administrations of OSK to humans. KHL has identified no publicly documented earlier human OSK administration and is continuing to assemble and review the treatment chronology before making an unqualified worldwide-first claim.
The chronology is potentially significant. Life Biosciences publicly announced on June 9, 2026 that it had dosed the first participant in its Phase 1 trial of ER-100, an investigational therapy using controlled expression of OCT4, SOX2 and KLF4 for optic neuropathies.
The Triple Helix treatments differ substantially in purpose and application. They use an 11-gene therapy containing OSK, delivered submucosally, with cognitive function as the principal target rather than localized treatment of the eye.
“This is not an announcement that we have proved that OSK reverses cognitive decline,” Scott said. “It is an announcement that human application has begun. Now we can monitor what actually happens, learn from it and adapt.”
KHL will present early observations from the human treatments in Madrid. These observations are preliminary and do not establish that OSK, the 11-gene therapy or any individual component caused the changes observed.
Sewell sees the treatments as part of a larger change taking place in the practicality of gene therapy.
“Gene therapy is becoming increasingly practical,” Sewell said. “I’ve already seen the cost of the technology fall dramatically. The next challenge is moving credible science into responsible human application and learning from what happens.”
They Helped Develop It. Then They Went First.
The second application is personal.
Patrick Sewell, Kenneth Scott and Helga Sands worked together to develop the application therapy that became the KHL Rejuvenation Cocktail.
Sewell and Triple Helix Science brought gene-therapy science and technical expertise. Scott and Sands were actively involved in developing and modifying the application therapy around the requirements of people in later life—the population KHL was created to serve.
Then Scott and Sands became its first two recipients.
“We would not ask other people to go first,” Scott said.
The Rejuvenation Cocktail combines Follistatin, Klotho and SIRT1, addressing three areas of particular importance in later life: muscle, cognitive function and metabolism.
During approximately five months of monitoring, Scott and Sands have observed changes including increased muscle and strength and fasting blood glucose declining from approximately 100 mg/dL to approximately 75 mg/dL. Sands has experienced the virtual disappearance of previous bruising. Both also report an unexpected disappearance of the jet lag that had routinely accompanied their transatlantic travel.
These observations involve only the first two recipients. They are not results from a controlled clinical trial and do not establish that the therapy, or any individual component, caused the changes observed.
For KHL, however, unexpected observations are part of the reason human application matters.
“Mice can tell us an enormous amount,” Scott said. “But none of the mice reported that their jet lag disappeared.”
DAMA therefore does not end with application. It proceeds to Monitor and Adapt.
The People Who Need It Now
The conventional development of a new drug or biologic can take more than a decade.
For Scott and Sands, and for the population KHL seeks to serve, that creates a fundamental problem.
“My actuarial life expectancy is about seven years. Helga’s is about six,” Scott said. “If development takes thirteen years, telling us to wait is not a solution.”
KHL’s focus is consequently different from much of the longevity field. It is concerned particularly with older people already experiencing functional decline and with what can be done to restore lost function during their remaining lives.
“There is extraordinary rejuvenation science being developed for the future,” Scott said. “Our concern is the people who need it now.”
KHL works with researchers and biotechnology developers to identify promising rejuvenative technologies, help adapt them for application to people in later life, bring together the necessary scientific, clinical and financial resources, and learn systematically from human application.
The Foundation is seeking additional scientists, physicians and biotechnology companies with rejuvenative technologies that may benefit from this approach, as well as investors, collaborators and prospective participants interested in KHL programs.
The Human Learning Phase Has Begun
Scott’s Madrid presentation, “Stop Aging. Start Rejuvenating.”, brings the Rejuvenation Cocktail, the human OSK treatments and DAMA together around a single proposition.
Cells have been rejuvenated.
Animals have been rejuvenated.
Human application has begun.
“We don’t yet know how well these therapies will work in humans,” Scott said. “That is precisely why the human learning phase matters.”
About KHL Foundation
KHL Foundation was founded by Kenneth Scott and Helga Sands to bring rejuvenative therapies to older people who are already experiencing age-related decline and do not have decades to wait for conventional development pathways.
KHL works with scientists, physicians and biotechnology developers to help develop and adapt promising rejuvenation technologies for practical human application. Its operating model—Develop → Apply → Monitor → Adapt—uses carefully monitored human application as part of an iterative process of learning and improvement.
About Triple Helix Science
Triple Helix Science, led by Patrick Sewell, MD, develops gene and regenerative therapies spanning longevity, neurodegeneration, metabolic health, muscle biology and other therapeutic areas.
Madrid Presentation
Stop Aging. Start Rejuvenating.
Kenneth Scott, Co-Founder, KHL Foundation
International Longevity Summit Madrid 2026
Royal National Academy of Medicine of Spain
September 30, 2026 — 18:00 CEST
Media and interview inquiries: ken@khlfoundation.com